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Chana series are new chalcone derivatives. To evaluate the 
possibility of Chana series as therapeutic agents of type 2 dia-
betes, the inhibitory effects of Chana series on the activities of 
α-glucosidase and DPP-4 were investigated using in vitro en-
zyme assays, and their effects on adipocyte differentiation 
were investigated in C3H10T1/2 cells. Chana 1 and Chana 7 
among the Chana series showed significant inhibition of α-glu-
cosidase activity. In DPP-4 enzyme assay, Chana 1 exhibited 
the highest inhibitory activity while Chana 7 did not. In MTT 
assay, Chana 1 did not show significant cytotoxicity up to a 
concentration of 250 μM, whereas cytotoxicity was observed 
with Chana 7 at a concentration of 300 μM. In addition, 
Chana 1 induced adipocyte differentiation. Therefore, Chana 1 
showed inhibitory effects on α-glucosidase and DPP-4 as well 
as a stimulatory effect on adipocyte differentiation, suggesting 
that Chana 1 may be a potential beneficial agent for the treat-
ment of type 2 diabetes. [BMB reports 2011; 44(6): 410-414]
INTRODUCTION
Diabetes has become increasingly common around world-
wide. Type 2 diabetes, in particular, is caused by a metabolic 
disorder characterized by hyperglycemia and insulin resistance 
(1-3). Various therapeutic approaches have been used to alle-
viate diabetes, including improvement of insulin sensitivity, in-
hibition of gluconeogenesis, and reduction of absorption of 
glucose from the intestine (4). The goal of treatment of type 2 
diabetes mellitus is generally maintenance of glycemic control 
in the postprandial state as well as the fasting state (5). 
α-Glucosidase is a membrane-bound enzyme at the epi-
thelium of the small intestine and plays a key role in carbohy-
drate digestion (6). Inhibition of α-glucosidase leads to the de-
lay or reduction of increased postprandial blood glucose 
levels. Acarbose, a well established α-glucosidase inhibitor, 
significantly decreases postprandial plasma glucose and HbAlc 
levels (7). Thus, α-glucosidase inhibitors have been proposed 
as a potential therapeutic target for drug discovery in the treat-
ment of type 2 diabetes (8, 9).
Two gut hormones, glucagon-like peptide 1 (GLP-1) and glu-
cose-dependent insulinotropic polypeptide (GIP), function as 
incretins that increase insulin secretion from β-cells after enter-
al nutrient ingestion (10). Recently, clinical evidence has sug-
gested that incretin-based therapies may be useful for the man-
agement of type 2 diabetes (11, 12). Dipeptidyl peptidase-4 
(DPP-4) inhibitors improve hyperglycemic conditions by stabi-
lizing postprandial levels of GLP-1 and GIP in patients with 
type 2 diabetes and have been approved as a target for the 
treatment of type 2 diabetes (13, 14).
Licorice, which is used as a traditional medicine, originates 
from the root and stolon of Glycyrrhiza plant species (Legumi-
nosae). Six retrochalcone, licochalcone A-E, and echinatin 
have been isolated from the roots of G. inflate, a Glycyrrhiza 
species member. It was previously reported that these retro-
chalcones have various biological activities, including an-
ti-cancer, anti-bacterial, anti-oxidative, and anti-inflammatory 
effects (15-17). In this study, we synthesized new chalcone de-
rivatives, Chana series, and evaluated their novel inhibitory ef-
fects on the enzyme activities of α-glucosidase and DPP-4 and 
adipocyte differentiation in vitro. 
RESULTS AND DISCUSSION
Effects on α-glucosidase activity 
To identify α-glucosidase inhibitors, 10 pure synthetic com-
pounds of new retrochalcone derivatives were used in this 
assay. In vitro α-glucosidase assay found that both Chana 7 
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Fig. 1. Effect of Chana 7 on α-glucosidase activity in vitro. α- 
Glucosidase was dissolved at a concentration of 2 units/ml and 
was used as an enzyme source; 5 mM para-Nitrophenyl-α-D-glu-
copyranoside was used as a substrate. Ten microliters of each 
Chana 7 dilution or Acarbose were mixed with 50 μl of reaction 
buffer and 20 μl of enzyme. Finally, 20 μl of substrate was add-
ed and incubated for 10 min at 37oC. After incubation, the ab-
sorbance was measured at 405 nm. The error bars represent the 
standard error of the mean.
Table 1. Effects on α-glucosidase inhibition activity of synthesized 
Chana series
Compound (1 mM)
α-glucosidase
Inhibition ratio (%)
Chana 1 63.1 ± 3.3
Chana 2 13 ± 1.5
Chana 3 32.1 ± 2.8
Chana 4 9.2 ± 0.9
Chana 5 1.8 ± 1.1
Chana 6 18.9 ± 1.7
Chana 7 92.1 ± 2.2
Chana 8 22.5 ± 2.0
Chana 9 19.4 ± 1.2
Chana 10 27.3 ± 2.2
Table 2. DPP-4 inhibitory activity of Chana 1 and Chana 7
Compound (1 mM)
DPP-4
Inhibition ratio (%)
Chana 1 48.1 ± 2.4
Chana 7 0
and Chana 1 had more potent effects than other Chana series 
(Table 1). The inhibition rates of Chana 7 and Chana 1 at a 
concentration of 1 mM were 92.1% and 63.1%, respectively. 
Thus, we selected Chana 7 due to its high inhibition rate and 
examined its α-glucosidase inhibition activity at various con-
centrations (0.062-1 mM). Chana 7 inhibited α-glucosidase ac-
tivity in a concentration-dependent manner (Fig. 1). Intere-
stingly, Chana 7 inhibited α-glucosidase more effectively than 
acarbose, the positive control. Therefore, Chana 1 and Chana 
7 showed strong inhibitory effects on α-glucosidase activity. 
By extension, these results suggest that Chana 1 and Chana 7 
are effective α-glucosidase inhibitors.
Effects on DPP-4 activity 
The effects of Chana 1 and Chana 7 on DPP-4 activity were 
measured using in vitro enzyme assay. As shown in Table 2, 
Chana 1 at a concentration of 1 mM significantly decreased 
DPP-4 activity to 48.1%. However, Chana 7 at a concentration 
of 1 mM did not show any effect on DPP-4 activity. Therefore, 
Chana 1 inhibited DPP-4 activity, which implies it could be a 
novel therapeutic agent for the treatment of type 2 diabetes.
Effects on cell viability 
MTT assay was conducted after treatment with Chana 1 and 
Chana 7 for 48 h at concentrations of 50-1,200 μM. The re-
sults demonstrate that Chana 1 exerted no inhibitory effects on 
cell viability up to a concentration of 250 μM (Fig. 2A), where-
as cell viability in the presence of Chana 7 was significantly re-
duced at a concentration of 300 μM (Fig. 2B). Therefore, the 
side effect of Chana 1 on cell viability was lower than that of 
Chana 7. 
Effect on adipocyte differentiation of C3H10T1/2 multipotent 
stem cells
To determine the effects of Chana 1 on adipocyte differ-
entiation, C3H10T1/2 multipotent stem cells were treated with 
Chana 1 at a concentration of 10 μM for 8 days during stand-
ard adipogenic induction. Rosiglitazone (rosi), a PPARγ ago-
nist, was used as a positive control of adipocyte differentiation. 
The rosi positive control strongly induced adipocyte differ-
entiation in C3H10T1/ 2 cells (Fig. 3A). Treatment with Chana 
1 at a concentration of 10 μM induced lipid accumulation, as 
detected by both Oil red O staining for lipid droplets and spec-
trophotometric quantification of extracted Oil red O stains 
(Fig. 3A and B). Therefore, Chana 1 induced adipocyte 
differentiation. In previous studies, in vitro adipocyte differ-
entiation as a model for testing insulin sensitivity was used to 
screen novel anti-diabetic drugs (18, 19). Further, several stud-
ies reported that natural pure compounds that promote adipo-
cyte differentiation can be used for the treatment of type 2 dia-
betes (20, 21). Therefore, Chana 1 may have exerted a benefi-
cial effect on type 2 diabetes.
In conclusion, Chana 1 and Chana 7 demonstrated inhi-
bitory activity on α-glucosidase, and Chana 1 had an in-
hibitory effect on DPP-4. In addition, Chana 1 stimulated adi-
pocyte differentiation in vitro. These results may provide evi-
dence that a new chalcone derivative, Chana 1, is a novel 
agent for the treatment of type 2 diabetes. Further study is 
needed to prove whether or not chalcone derivatives improve 
diabetes in vivo.
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Fig. 2. Effects of Chana 1 and Chana 7 on cell viability. (A) To investigate the toxicity of Chana 1 on cell viability, PC 3 cells were in-
cubated in the presence of Chana 1 at concentrations of 0, 50, 125, 250, 500, and 1,000 μM, after which cell viability was evaluated 
via MTT assay after 48 h. (B) To investigate the toxicity of Chana 7 on cell viability, PC 3 cells were incubated in the presence of 
Chana 7 at concentrations of 0, 50, 150, 300, 600, and 1,200 μM, after which was evaluated via MTT assay after 48 h. The error bars 
represent the standard error of the mean. 
Fig. 3. Effect of Chana 1 on adipocyte differentiation of 
C3H10T1/2 cells. (A) C3H10T1/2 cells were treated with Chana 7 
(10 μM) or rosiglitazone (Rosi, 1 μM) during adipocyte differ-
entiation for 8 days. Control was differentiated by standard adipo-
genic induction media without treatment. The adipogenesis of 
C3H10T1/2 cells was visualized by Oil Red O staining. Microsco-
pic pictures were taken at day 8 with ×100 magnification. (B) 
Oil Red O stain was extracted with isopropanol. The absorbance 
of the extracted Oil Red O stain was determined spectrophoto-
metrically at 570 nm in order to measure triglyceride (TG) accu-
mulation. The symbol *indicates significant difference at P ＜ 0.01
(C) The chemical structure of Chana 1.
MATERIALS AND METHODS
α-Glucosidase enzyme assay
Inhibitory activity against α-glucosidase was measured accord-
ing to the method described previously (8) with minor modi-
fications. Briefly, α-glucosidase (Sigma, St Louis, MO, USA) 
was dissolved at a concentration of 2 units/ml in reaction buf-
fer (100 mM phosphate buffer and 0.02% sodium azide) and 
used as an enzyme source; 5 mM para-Nitrophenyl-α-D-gluco-
pyranoside (Sigma, St Louis, MO, USA) was used as a sub-
strate. Firstly, we carried out the α-glucosidase inhibition assay 
with Chana series at a concentration of 1 mM. Then, solutions 
of Chana 7 among the Chana series at concentrations of 0.062, 
0.125, 0.25, 0.5, and 1 mM were made by serial dilution. Ten 
microliters of each Chana 7 dilution was mixed with 50 μl of 
reaction buffer and 20 μl of enzyme source. Finally, 20 cl of 
substrate was added and incubated for 10 min at 37oC. After 
incubation, the O.D. was measured at 405 nm using an MRX 
II microplate reader (Dynatech Labs., Chantilly, VA, USA). 
Acarbose was used as a positive control. The α-glucosidase in-
hibition ratio was calculated as follows: α-glucosidase in-
hibition ratio (%) = [(O.D. of control × O.D. of test sample) / 
O.D. of control] × 100. All assays were conducted in tripli-
cate, and at least three separate assays were performed.
DPP-4 enzyme assay
Inhibitory activity against DPP-4 was measured by the method 
proposed by Tanaka-Amino et al. (22) with minor modifications. 
Briefly, DPP-4 activity was determined by the rate of hydrol-
ysis of a surrogate, H-Gly-Pro-AMC (AMC; 7-amino-4-methyl-
coumarine). Then, 20 μl of enzyme was added to each well of 
a black 96-well flat-bottom plate, followed by addition of 20 μl 
of assay buffer (25 mM HEPES, 140 mM NaCl, 1% RIA-grade 
BSA, pH 7.8) containing 80 mM MgCl2, followed by 20 μl of 
Chana 1 and 7 at the indicated concentrations. The reaction 
was initiated by adding 20 μl of assay buffer containing 200 
μM H-Gly-Pro-AMC. After being incubated at room temper-
ature for 15 min, the fluorescence emitted by librated AMC 
was measured at 405 nm using an MRX II microplate reader 
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(Dynatech Labs., Chantilly, VA, USA). All assays were con-
ducted in triplicate, and at least three separate assays were per-
formed
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide 
(MTT) assay
The cells (1 × 104 cells/well) were plated and incubated for 24 
h in 96-well plates with the indicated concentrations of Chana 
1 and Chana 7. After 48 h, MTT (Sigma-Aldrich, St. Louis, MO, 
USA) was employed to measure cell viability, in accordance 
with the manufacturer’s instructions. The absorbance at 570 
nm was measured with an MRX II microplate reader (Dyna-
tech Labs, Chantilly, VA, USA).
Adipocyte differentiation assay
C3H10T1/2 cells (American Type Culture Collection, Rock-
ville, MD, USA) were grown in Dulbecco's Modified Eagle's 
Medium (DMEM) containing fetal bovine serum (FBS), 100 
U/ml of penicillin, and 100 μg/ml of streptomycin in a humidi-
fied incubator under an atmosphere of 5% CO2 at 37oC. 
C3H10T1/2 cells at 2 days post-confluence (day 0) were stimu-
lated to differentiate in standard adipogenic medium (DMEM 
containing 10% FBS, 0.5 μM isobutylmethylxanthine, 1 μM 
dexamethasone, and 1 μg/ml of insulin) for 2 days (23, 24). 
The differentiation medium was replaced after 2 days with 
DMEM containing 10% FBS and 1 μg/ml of insulin, followed 
by exchange with DMEM containing 10% FBS every day 
thereafter. During adipocyte differentiation, C3H10T1/2 cells 
were treated with 10 μM Chana 1 from days 0 to 8, followed 
by treatment with 1 μM rosi as a positive control. All assays 
were conducted in triplicate, and at least three separate assays 
were performed. 
Quantification of lipid accumulation
In order to determine the degree of differentiation and visual-
ize lipid accumulation, cytoplasmic triglycerides in the cells 
were stained with Oil Red O (Sigma-Aldrich, St.Louis, MO, 
US) as previously described (23, 24). The stained cells were 
photographed at a magnification of ×100 using an Olympus 
CKX41 inverted microscope system (Tokyo, Japan). After the 
Oil Red O retained in the cells was extracted with isopro-
panol, the absorbance was determined spectrophotometrically 
at 570 nm using an MRX II microplate reader (Dynatech Labs., 
Chantilly, VA, USA). 
Statistical analysis
The SPSS 12.0 statistical package program (SPSS Inc. Chicago, 
IL, USA) was utilized for all statistical analyses. All data in the 
same groups were assessed via paired t-tests. A P value of ＜ 
0.05 was considered to be indicative of a statistically sig-
nificant difference.
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